This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT07177469 |
|---|---|
| Status | Completed |
| Phase | Phase 2 |
| Sponsor | The United Bio-Technology (Hengqin) Co., Ltd. |
| Enrollment | 205 participants |
| Design | Interventional, Randomized, Parallel, Double-blind, Placebo-controlled |
| Conditions | Obesity; Overweight |
| Interventions | UBT251 Injection 2.0 mg; UBT251 Injection 4.0 mg (initial dose 0.5 mg); UBT251 Injection 4.0 mg (initial dose 1.0 mg); UBT251 Injection 6.0 mg; Placebo |
| Start | Mar 14, 2025 |
| Primary completion | Oct 22, 2025 |
| Study completion | Nov 19, 2025 |
| Results posted | Not yet |
| Registry last updated | Not stated |
Compounds on this site that cite this trial
What the registry says the trial is about
Randomized, double-blind, parallel, placebo-controlled phase 2 study of UBT251 injection in adults with overweight or obesity. Results are published in Cell Metabolism.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Percentage change in body weight from baseline after 24 weeks of treatment | Week 24 |
19 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 1, 2026. See the trial changes feed for what has changed recently.
More trials of UBT251
- UBT251 Phase 3 in Overweight or Obesity (China) (Phase 3 NCT07648225)
- UBT251 Safety, Tolerability and Efficacy in Overweight or Obesity (Novo Nordisk Phase 2) (Phase 2 NCT07395687)
- UBT251 Injection Phase II Clinical Study (CKD) (Phase 2 NCT07134335)
- A Research Study Looking Into How UBT251 Works With Birth Control Tablets and Emptying of the (Phase 1 NCT07710729)
- A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood (Phase 1 NCT07710768)
- UBT251 Injection Phase Ⅲ Study (OSA-PAP) (Phase 3 NCT07806851)
Research area: Metabolic and incretin. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.
